Andreas Kirberg

Professional Background

Almost 25 years of professional experience
Andreas worked as a consultant for some major clients like Siemens, BMW and Sun Microsystems
He also worked as a manager for different large pharmaceutical corporations (ratiopharm and STADA Arzneimittel AG) where he participated in large integration and global M&A projects including carve-outs
Andreas is a Key Player in an award-winning cross-company initiative designing and realizing an innovative training for knowledge transfer within post-merger integrations as well as M&A
He speaks fluent German and English

M&A Skills & Expertise

Andreas has senior executive experience with an extensive international track record in general management, business development, merger & acquisition, integration-, risk-, portfolio- and project management, as well as innovation and patent affairs within the health care and pharmaceutical market
His experience spectrum covers executive board membership and close collaboration with supervisory board as well as other members of C-level management
Andreas was the manager in charge of the post-merger integration of Teva/ratiopharm Germany in close contact with the European headquarter
Andreas developed a wide international and multi-cultural experience working in several countries including America, Europe, Middle East and Asia

Project Highlights

Teva/ratiopharm, leading the Germany integration of the €3.6bn acquisition of ratiopharm including prior carve-out of Suisse operations with Sales of €150m
Integrated brand product portfolio acquired from Grünenthal into STADA’s R&D organization in the Middle & Eastern Europe, Russia and the Middle East (transaction volume € 312m)
Acquisition and integration of Thornton+ Ross a British OTC company (transaction volume € 260m) with Sales in over 60 countries
Acquisition and integration of Sciotec, an Austrian OTC company (transaction volume €17.2m)
Planned and executed strategic initiative Expansion Latin America; performed market potential analysis identified main markets and conducted two due diligences in Brazil and Columbia
Acquisition and integration of Argentinian generics producer Laboratorio Vannier S.A. (transaction volume €12m)